<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRIAMCINOLONE ACETONIDE- triamcinolone acetonide tablet </strong><br>Boehringer Ingelheim Vetmedica, Inc.<br></p></div>
<h1><span class="Bold">Triamcinolone Acetonide Tablets</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8e8abf7b-b3e0-4ef4-b08f-1553663f8ad1"></a><a name="section-1"></a><p></p>
<p class="First">NADA 137-694, Approved by FDA</p>
<p>For oral use in dogs and cats only.</p>
<p><span class="Bold">Caution: </span>Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_bd6a65c5-0cde-46f1-a20d-6d76db2318db"></a><a name="section-2"></a><p></p>
<h1>Description</h1>
<p class="First">Triamcinolone acetonide is a highly potent synthetic glucocorticoid and anti-inflammatory agent.<span class="Bold"><span class="Sup">1 </span></span> Its advantage over the older corticoids lies in its ability to achieve equal anti-inflammatory effect with a lower dose.<span class="Bold"><span class="Sup">2 3 4 </span></span>Triamcinolone has very weak sodium-retaining effects and is probably the least electrolyte-retaining compound of the corticosteroid group.<span class="Bold"><span class="Sup">2 4 </span></span>Triamcinolone has a plasma half-life of approximately 300 minutes and is classified as an intermediate acting glucocorticoid, whereas the acetonide salt has a longer duration of action and a higher lipid-water distribution coefficient.<span class="Bold"><span class="Sup">1 2 3 4 </span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_59a44dbf-161e-438f-a9db-b9a29f17f64f"></a><a name="section-3"></a><p></p>
<h1>Indications</h1>
<p class="First">Triamcinolone acetonide is a highly potent glucocorticoid effective in the treatment of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and related disorders in dogs and cats. It is indicated in the management and treatment of <span class="product-label-link" type="condition" conceptid="4000634" conceptname="Acute arthritis">acute arthritis</span> and allergic and dermatologic disorders.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_dda4059e-7e22-484b-8595-8cf9f2bf2a04"></a><a name="section-4"></a><p></p>
<h1>Dosage and Administration</h1>
<p class="First">The keystone of satisfactory therapeutic management with triamcinolone acetonide, as with other steroids, is individualization of dosage in reference to the severity of the disease, the anticipated duration of steroid therapy and the animal’s threshold or tolerance for steroid excess. The prime objective of steroid therapy should be to achieve a satisfactory degree of control with a minimum effective dose. </p>
<p>The initial suppressive dose level of 0.5 -1.0 mg per 10 pounds of body weight daily should be administered until a satisfactory clinical response is obtained, a period not to exceed 14 days. If a satisfactory response is not obtained in 14 days, re-evaluation of the case to confirm the original diagnosis should be made. As soon as a satisfactory clinical response is obtained, the daily dose should be reduced gradually, either to termination of treatment in the case of acute conditions (e.g., seasonal <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, acute ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammations</span>) or to the minimal effective maintenance dose level in the case of chronic conditions (e.g., <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>). Symptoms of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> following withdrawal may persist for several days, weeks or years. Some cases have resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. To minimize the adverse effects from withdrawal or reduction in dosage, cautiously decrease dosage in a gradual manner. In dogs, dosing in the morning may also be beneficial in minimizing effects because nocturnal pituitary/adrenal activity will be less inhibited. In chronic conditions, and in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> especially, it is important that the reduction in dosage from initial to maintenance dose levels be accomplished slowly. The maintenance dose level should be adjusted from time to time as required by fluctuation in the activity of the disease and the animal’s general status. Maintenance dosage levels of 0.125-0.25 mg per 10 pounds of body weight daily are recommended. Accumulated experience has shown that the long-term benefits to be gained from continued steroid maintenance are probably greater the lower the maintenance dose level. In <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> in particular, maintenance steroid therapy should be at the lowest possible level. </p>
<p><span class="Bold">Important: </span>In the therapeutic management of animals with chronic diseases, such as <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, triamcinolone should be regarded as a highly valuable adjunct, to be used in conjunction with but not as a replacement for standard therapeutic measures.</p>
<p><span class="Bold">Recommended Dosage Schedule:</span></p>
<table>
<col width="11%">
<col width="19%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Body</span></p>
<p><span class="Bold">Weight</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Initial</span></p>
<p><span class="Bold">Daily Dosage</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Maintenance</span></p>
<p><span class="Bold">Daily Dosage</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">  5 lbs</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">0.25 to 0.5 mg</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">0.0625 to 0.125 mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">10 lbs</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">  0.5 to 1.0 mg</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">    0.125 to 0.25 mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">20 lbs</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">  1.0 to 2.0 mg</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">      0.25 to 0.50 mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">30 lbs</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">  1.5 to 3.0 mg</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">    0.375 to 0.75 mg</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">60 lbs</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">  3.0 to 6.0 mg</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">      0.75 to 1.50 mg</span></p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_a78d5799-e3f2-4fd0-b165-3162c69c13ee"></a><a name="section-5"></a><p></p>
<h1>Contraindications</h1>
<p class="First">Do not use in <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span>. Except for emergency therapy, do not use in animals with <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, <span class="product-label-link" type="condition" conceptid="312358" conceptname="Chronic glomerulonephritis">chronic nephritis</span>, <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> syndrome and <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>. Existence of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> are relative contraindications.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_bf5a2cfb-9aef-4a5c-8ad2-30b976397862"></a><a name="section-6"></a><p></p>
<h1>Warning</h1>
<p class="First">Not for human use. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>, <span class="product-label-link" type="condition" conceptid="4003030" conceptname="Retained placenta">retained placenta</span> and metritis. </p>
<p>Additionally, corticosteroids administered to dogs, rabbits and rodents during pregnancy have produced <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>. Other congenital anomalies including deformed forelegs, <span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">phocomelia</span> and <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">anasarca</span> have been reported in the offspring of dogs which received corticosteroids during pregnancy.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_492cb2a2-0233-484f-97ed-55ecb9f95dbf"></a><a name="section-7"></a><p></p>
<h1>Precautions</h1>
<p class="First">Because of its inhibitory effect on fibroplasia, triamcinolone may mask the signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and enhance dissemination of the infecting organism. Hence, all animals receiving triamcinolone should be watched for evidence of intercurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Should <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occur, it must be brought under control by use of appropriate antibacterial measures or administration of triamcinolone should be discontinued.</p>
<p>Because this anti-inflammatory steroid manifests little sodium-retaining activity, the usual early sign of cortisone or hydrocortisone overdosage (i.e., increase in body weight due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>) is not a reliable index of overdosage. Hence, recommended dosage levels should not be exceeded, and all animals receiving triamcinolone acetonide should be under close medical supervision.</p>
<p>Use of corticosteroids may result in the inhibition of endogenous steroid production which sometimes persists for weeks following drug withdrawal. In patients presently receiving or recently withdrawn from corticosteroid treatments, administration of a rapid acting corticosteroid before, during and after an unusually stressful situation is recommended. </p>
<p>Single or multiple doses of 1 mg/kg of a corticosteroid induced hepatopathy in the dog and rabbit in a study by Rogers and Ruebner in 1977.<span class="Bold"><span class="Sup">4 </span></span>The condition was determined in the dog by a biopsy of the liver and was accompanied by elevated serum glutamic-pyruvic transaminase, SAP and SGGT (in some dogs) and increased bromsulphalein retention.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_d3907db9-28b3-422f-8c3f-b68ba51d640b"></a><a name="section-8"></a><p></p>
<h1>Adverse Reactions</h1>
<p class="First">As with the use of any corticosteroid, side effects and metabolic alterations can be anticipated when treatment is intensive or prolonged. In animals with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, use of triamcinolone acetonide may be associated with an increase in the insulin requirement. Negative nitrogen balance may occur, particularly in animals that require protracted maintenance therapy.<span class="Bold"><span class="Sup">3 4 5 </span></span><span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">Polydipsia</span> or <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> may occur with high dosage or frequent administration. The likelihood of their occurrence may be minimized by giving as brief a course of corticosteroid therapy as possible, and by waiting for the reappearance of symptoms before repeating therapy. If <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span> or <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> should occur, therapy should then be resumed at a lower dosage level.</p>
<p>Other adverse reactions that have occurred with the use of corticosteroids are SAP and SGPT enzyme elevations, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (occasionally bloody). <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have occasionally been seen following administration. Cushing’s syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.</p>
<p>To report suspected adverse reactions, to obtain a Material Safety Data Sheet (MSDS) or for technical assistance, call 1-866-638-2226.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_358c7152-cbdc-4548-bd60-aa9425b81705"></a><a name="section-9"></a><p></p>
<h1>Clinical Pharmacology</h1>
<p class="First">Glucocorticoids exert a regulatory influence on <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, erythrocytes and eosinophils of the blood and on the structure and function of lymphoid tissues.<span class="Bold"><span class="Sup">1 4 5 </span></span>A primary feature of the glucocorticoids is their anti-inflammatory activity with minimum sodium and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, which is often associated with the mineralocorticoids. <span class="Bold"><span class="Sup">1 2 3 4 5 6 </span></span>Glucocorticoids not only inhibit the early phases of the inflammatory process (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, fibrin deposition, capillary dilatation, migration of leukocytes into the inflamed area and phagocytic activity) but also the later manifestations (capillary proliferation, fibroblast proliferation and deposition of collagen).<span class="Bold"><span class="Sup">3 4 6 </span></span>The exact mechanism is not known, but the glucocorticoids obviously suppress normal tissue response to injury and alleviate symptoms from many conditions.<span class="Bold"><span class="Sup">2</span></span></p>
<p>As with other adrenal steroids, triamcinolone acetonide has been found useful in alleviating the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and lameness associated with acute localized arthritic conditions and generalized arthritic conditions. Glucocorticoids have been used successfully to treat traumatic <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> and generalized arthritic conditions in dogs. Remission of musculoskeletal conditions may be permanent, or symptoms may recur, depending on the cause and extent of structural degeneration.<span class="Bold"><span class="Sup">1 2 3 4 5 </span></span>Glucocorticoids also relieve <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>, acute moist <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, dry <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, pollen sensitivities and <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span> in dogs and <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span> and moist and dry <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span> in cats. Symptoms may be expected to recur if the cause of the <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> is still present, in which case retreatment may be indicated. In treating acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, appropriate treatment such as intravenous prednisolone sodium succinate should be used.<span class="Bold"><span class="Sup">1 2 3 4 5</span></span></p>
<p>In dogs and cats moribund from overwhelmingly severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> for which antibacterial therapy is available (e.g., critical <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, pyometritis), a glucocorticoid may be lifesaving, acting to inhibit the <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammatory reaction</span>, which itself may be lethal; preventing <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vascular collapse</span> and preserving the integrity of the blood vessels; modifying the animal’s reaction to drugs; and preventing or reducing the exudative reaction which often complicates certain <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. As supportive therapy, it improves the general attitude of the animal being treated. All necessary procedures for the establishment of a bacterial diagnosis should be carried out whenever possible before institution of therapy. Corticosteroid therapy in the presence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should be administered for the shortest possible time compatible with maintenance of an adequate response, and antibacterial therapy should be continued for at least three days after the hormone has been withdrawn. Combined hormone and antibacterial therapy does not obviate the need for indicated surgical treatment.<span class="Bold"><span class="Sup">1 2 3 4 5 6</span></span></p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_8c48e834-1954-474c-95f9-b5d793b7f56e"></a><a name="section-10"></a><p></p>
<h1>Storage</h1>
<p class="First">Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (59º and 86ºF).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_5a193b82-21d1-4d15-a28f-b6b5bd4ba38d"></a><a name="section-11"></a><p></p>
<h1>How Supplied</h1>
<p class="First">Triamcinolone Acetonide Tablets are available in two strengths, 0.5 and 1.5 mg.</p>
<p>NDC-0010-6876-01 - 0.5 mg - 1,000 tablets</p>
<p>NDC-0010-6877-01 - 1.5 mg - 500 tablets</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_7bff19d6-8c5b-42b8-93ec-52ce14126667"></a><a name="section-12"></a><p></p>
<h1>References</h1>
<p class="First">1. Osol, A., ed., 1980. <span class="Italics">Remington's Pharmaceutical Sciences</span>, 16th Edition. Mack Publishing Company, Easton, PA. 898-901, 911.</p>
<p>2. <span class="Italics">Martindale, The Extra Pharmacopoeia</span>, 27th Edition, 1977.  The Pharmaceutical Press, London, England. 389-396, 432-433.</p>
<p>3. Gilman, A.G., L.S. Goodman and A. Gilman, eds., 1980. <span class="Italics">The Pharmacological Basis of Therapeutics</span>, 6th Edition. Macmillan Publishing Co., Inc., New York, NY. 1470-1496.</p>
<p>4. Booth, N.H. and L.E. McDonald, eds., 1982. <span class="Italics">Veterinary Pharmacology and Therapeutics</span>, 5th Edition. The Iowa State University Press, Ames, IA. 553-570.</p>
<p>5. DiPalma, J.R., ed., 1976. <span class="Italics">Basic Pharmacology in Medicine. </span>McGraw-Hill, Inc., St. Louis, MO.       328-337.</p>
<p>6. Kirk, R.W., ed., 1980. <span class="Italics">Current Veterinary Therapy VII, Small Animal Practice</span>. W.B. Saunders Company, Philadelphia, PA. 497-500, 992-994.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e5c90fcd-2ac1-4633-b192-c6d7091c7be6"></a><a name="section-13"></a><p></p>
<p class="First">Manufactured for:<br><span class="Bold">Boehringer Ingelheim Vetmedica, Inc.<br></span>St. Joseph, MO 64506 U.S.A.<br></p>
<p>Revised 06/2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_abc37b0c-22dc-47c5-87a4-9f3a6e77e404"></a><a name="section-14"></a><p></p>
<h1>Bottle Label, 0.5 mg, 1000 tablets</h1>
<div class="Figure">
<a name="id30964958"></a><img alt="Picture of 0.5 mg, 1000 count bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=149bdac2-3cef-4523-8f92-a18cfda8c4f3&amp;name=29f894da-8fef-46eb-8e9b-785de97b01c4-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_1d56cda3-f10f-4ece-9838-398b05b8e352"></a><a name="section-15"></a><p></p>
<h1>Bottle Label, 1.5 mg, 500 tablets</h1>
<div class="Figure">
<a name="id30964966"></a><img alt="Picture of 1.5 mg, 500 tablet label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=149bdac2-3cef-4523-8f92-a18cfda8c4f3&amp;name=29f894da-8fef-46eb-8e9b-785de97b01c4-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRIAMCINOLONE ACETONIDE 		
					</strong><br><span class="contentTableReg">triamcinolone acetonide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0010-6876</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TRIAMCINOLONE ACETONIDE</strong> (TRIAMCINOLONE ACETONIDE) </td>
<td class="formItem">TRIAMCINOLONE ACETONIDE</td>
<td class="formItem">0.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">4 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">0;5;251</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0010-6876-01</td>
<td class="formItem">1000  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA137694</td>
<td class="formItem">04/03/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRIAMCINOLONE ACETONIDE 		
					</strong><br><span class="contentTableReg">triamcinolone acetonide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0010-6877</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TRIAMCINOLONE ACETONIDE</strong> (TRIAMCINOLONE ACETONIDE) </td>
<td class="formItem">TRIAMCINOLONE ACETONIDE</td>
<td class="formItem">1.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">4 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">1;5;252</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0010-6877-01</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA137694</td>
<td class="formItem">04/03/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Boehringer Ingelheim Vetmedica, Inc.
							(007134091)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>29f894da-8fef-46eb-8e9b-785de97b01c4</div>
<div>Set id: 149bdac2-3cef-4523-8f92-a18cfda8c4f3</div>
<div>Version: 2</div>
<div>Effective Time: 20130418</div>
</div>
</div> <div class="DistributorName">Boehringer Ingelheim Vetmedica, Inc.</div></p>
</body></html>
